{"id":"direct-oral-challenge","safety":{"commonSideEffects":[{"rate":null,"effect":"Allergic reaction (urticaria, angioedema, anaphylaxis)"},{"rate":null,"effect":"Gastrointestinal symptoms (nausea, vomiting, abdominal pain)"},{"rate":null,"effect":"Respiratory symptoms (wheezing, dyspnea)"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a clinical diagnostic test rather than a therapeutic drug. The procedure involves giving a patient a measured dose of a suspected allergen or food/drug trigger by mouth while monitoring for objective signs of reaction (rash, respiratory changes, gastrointestinal symptoms, etc.). It is used to confirm or rule out IgE-mediated allergies, food intolerances, or drug sensitivities when history and skin/serological testing are inconclusive.","oneSentence":"Direct oral challenge is a diagnostic procedure that administers an allergen or suspected trigger orally under controlled medical supervision to assess allergic or adverse reactions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:35:19.104Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Confirmation of suspected food allergy"},{"name":"Confirmation of suspected drug allergy or intolerance"},{"name":"Assessment of allergic reaction severity"}]},"trialDetails":[{"nctId":"NCT06593756","phase":"NA","title":"Hemodynamic Monitoring and Fluid Responsiveness in Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO) - \"HemodynamECMOnitoring-VA Study\"","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-05-03","conditions":"ECMO Treatment, ARDS, Pneumonia","enrollment":30},{"nctId":"NCT06593717","phase":"NA","title":"Hemodynamic Monitoring and Fluid Responsiveness in Venovenous Extracorporeal Membrane Oxygenation (VV ECMO) - \"HemodynamECMOnitoring-VV Study\"","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-05-03","conditions":"ECMO Treatment, ARDS, Pneumonia","enrollment":30},{"nctId":"NCT07158619","phase":"NA","title":"Sustained Unresponsiveness (SU) to Cashew Nut Protein Following Oral Allergen-Specific Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2025-09","conditions":"Food Allergy in Children","enrollment":39},{"nctId":"NCT05464615","phase":"EARLY_PHASE1","title":"Geisinger Antibiotic Allergy Pilot Program: Assess and Address","status":"RECRUITING","sponsor":"Geisinger Clinic","startDate":"2024-03-04","conditions":"Penicillin Allergy","enrollment":100},{"nctId":"NCT07107451","phase":"NA","title":"Sustained Unresponsiveness (SU) to Sesame Protein Following Low-dose Oral Allergen-specific Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2025-08","conditions":"Food Allergy in Children","enrollment":39},{"nctId":"NCT07002814","phase":"","title":"Direct Oral Challenges in Private Practice Setting to Delabeling Children With Beta-lactam Allergy","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-06","conditions":"Allergy","enrollment":200},{"nctId":"NCT06303128","phase":"PHASE3","title":"Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge","status":"RECRUITING","sponsor":"James Tarbox, MD","startDate":"2024-02-03","conditions":"Penicillin Allergy","enrollment":380},{"nctId":"NCT06916819","phase":"NA","title":"Food Challenge at Home or in Medical Practice - the FoodCHOMP Study","status":"RECRUITING","sponsor":"Austin Health","startDate":"2025-04-16","conditions":"Food Allergies","enrollment":120},{"nctId":"NCT06755281","phase":"NA","title":"Risk-stratified Testing for Safe Removal of Penicillin Allergy Labels","status":"RECRUITING","sponsor":"Deniz Göcebe","startDate":"2025-01-08","conditions":"Penicillin Allergy, Hypersensitivity, Immediate, Hypersensitivity, Delayed","enrollment":100},{"nctId":"NCT03503058","phase":"PHASE2","title":"Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2022-05-07","conditions":"Malaria","enrollment":345},{"nctId":"NCT06414694","phase":"PHASE4","title":"Inpatient Penicillin Delabeling for Low-Risk Patients","status":"ENROLLING_BY_INVITATION","sponsor":"University of Tennessee","startDate":"2023-09-01","conditions":"Penicillin, Drug Allergy","enrollment":25},{"nctId":"NCT05847270","phase":"NA","title":"Surgical Treatment of Irreducible Atlantoaxial Dislocation","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-07-11","conditions":"Irreducible Atlantoaxial Dislocation","enrollment":70},{"nctId":"NCT06192277","phase":"NA","title":"Evaluation of a Direct Oral Penicillin Challenge in a Rural Community","status":"UNKNOWN","sponsor":"Northern Ontario School of Medicine","startDate":"2023-10-06","conditions":"Allergy Penicillin","enrollment":100},{"nctId":"NCT00887302","phase":"","title":"Metabolomics of Roux-en-Y Gastric Bypass (RYGB) With Gastrostomy","status":"COMPLETED","sponsor":"East Carolina University","startDate":"2009-03-25","conditions":"Type II Diabetes Mellitus, Obesity","enrollment":13},{"nctId":"NCT04620746","phase":"PHASE4","title":"Penicillin Allergy Testing in STD Clinics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-06-01","conditions":"Penicillin Allergy","enrollment":284},{"nctId":"NCT04454229","phase":"NA","title":"The Use of Penicillin Allergy Clinical Decision Rule to Enable Direct Oral Penicillin Challenge","status":"COMPLETED","sponsor":"Austin Health","startDate":"2021-07-01","conditions":"Hypersensitivity, Immediate, Hypersensitivity, Delayed, Hypersensitivity Response","enrollment":382},{"nctId":"NCT05016076","phase":"NA","title":"Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial","status":"WITHDRAWN","sponsor":"YingHsuanTai","startDate":"2022-05","conditions":"Obesity, Bariatric Surgery Candidate, Tracheal Intubation Morbidity","enrollment":""},{"nctId":"NCT02562872","phase":"PHASE1","title":"DSM265 Prophylaxis of Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2016-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT04310085","phase":"PHASE1","title":"Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2020-02-19","conditions":"Malaria,Falciparum, Parasitemia, Protozoan Infections","enrollment":16},{"nctId":"NCT03707041","phase":"PHASE1","title":"Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2018-11-16","conditions":"Malaria","enrollment":32},{"nctId":"NCT02450578","phase":"PHASE1","title":"DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2015-10","conditions":"Plasmodium Falciparum, Malaria","enrollment":22},{"nctId":"NCT03278808","phase":"PHASE2","title":"Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis","status":"WITHDRAWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2018-09-17","conditions":"Malaria","enrollment":""},{"nctId":"NCT02996695","phase":"PHASE1","title":"Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-04-06","conditions":"Plasmodium Falciparum Infection","enrollment":62},{"nctId":"NCT03757052","phase":"NA","title":"Amoxicillin Challenge for Penicillin Allergy Diagnosis","status":"UNKNOWN","sponsor":"CHU de Quebec-Universite Laval","startDate":"2018-11-20","conditions":"Penicillin Allergy","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Direct Oral challenge","genericName":"Direct Oral challenge","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Direct oral challenge is a diagnostic procedure that administers an allergen or suspected trigger orally under controlled medical supervision to assess allergic or adverse reactions. Used for Confirmation of suspected food allergy, Confirmation of suspected drug allergy or intolerance, Assessment of allergic reaction severity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}